The effect of dapagliflozin treatment on epicardial adipose tissue volume.
Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. · 2018
Read The effect of dapagliflozin treatment on epicardial adipose tissue volume. by Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5753537.txt.
Description
Sato and co-authors test whether a diabetes drug shrinks fat around the heart. The drug, dapagliflozin, makes the body pass sugar in urine and aids weight loss. Epicardial fat is a harmful depot linked to coronary disease. The team followed 40 diabetes patients with coronary artery disease for six months.
Half took dapagliflozin and half took standard care. The drug group lost weight and cut blood sugar more, they report. Heart fat volume fell clearly in the drug group, while it rose slightly in the other. Falls in heart fat tracked falls in weight and in TNF-α levels.
Catalog record
| CREATOR | Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |